Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab

Authors:

Abstract
Patients with unilateral neovascular AMD (nAMD) have considerable risk for conversion to choroidal neovascularization (CNV) in their fellow eye, with reported conversion rates of 12% to 22% at 2 years and 22% to 38.7% over 5 years.1-5 The largest study (to our knowledge) on the incidence of fellow eye conversion was the Age-Related Eye Disease Study (AREDS), in which 278 of 714 patients (38.9%) with unilateral nAMD experienced conversion to nAMD in their fellow eye over 6.3 years.6 While these prior reports provide important data for the general AMD population, data from large intravitreal anti–vascular endothelial growth factor (VEGF) treatment trials appear to show substantially higher nAMD conversion rates for patients, with unilateral nAMD ranging from 19% to 38% at 2 years.1,7

This publication has 25 references indexed in Scilit: